{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T23:50:00Z","timestamp":1783813800395,"version":"3.55.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1016\/j.leukres.2011.02.021","type":"journal-article","created":{"date-parts":[[2011,4,15]],"date-time":"2011-04-15T17:17:01Z","timestamp":1302887821000},"page":"991-997","source":"Crossref","is-referenced-by-count":42,"title":["Hematologic improvement and response in elderly AML\/RAEB patients treated with valproic acid and low-dose Ara-C"],"prefix":"10.1016","volume":"35","author":[{"given":"M.T.","family":"Corsetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Salvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Perticone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Baraldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"De Paoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Gatto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Pietrasanta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Pini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Primon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Zallio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Tonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.G.","family":"Alvaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Ciravegna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Levis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2011.02.021_bib0005","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/annonc\/mdj112","article-title":"Acute myelogenous leukemia in elderly patients not eligible for intensive chemotherapy: the dark side of the moon","volume":"17","author":"Latagliata","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.leukres.2011.02.021_bib0010","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.leukres.2011.02.021_bib0015","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00277-008-0477-9","article-title":"Current status of epigenetic treatment in myelodysplastic syndromes","volume":"87","author":"Kuendgen","year":"2008","journal-title":"Ann Hematol"},{"key":"10.1016\/j.leukres.2011.02.021_bib0020","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nature02625","article-title":"Epigenetics in human disease and prospects for epigenetic therapy","volume":"429","author":"Egger","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2011.02.021_bib0025","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1056\/NEJMra023075","article-title":"Gene silencing in cancer in association with promoter hypermethylation","volume":"349","author":"Herman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2011.02.021_bib0030","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/448548a","article-title":"Genomic biology: the epigenomic era opens","volume":"448","author":"Baylin","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2011.02.021_bib0035","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.1093\/emboj\/20.24.6969","article-title":"Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells","volume":"20","author":"Gottlicher","year":"2001","journal-title":"EMBO J"},{"key":"10.1016\/j.leukres.2011.02.021_bib0040","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","article-title":"The World Health Organization (WHO) classification of the myeloid neoplasms","volume":"100","author":"Vardiman","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.02.021_bib0045","doi-asserted-by":"crossref","first-page":"620","DOI":"10.7326\/0003-4819-103-4-620","article-title":"Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group","volume":"103","author":"Bennett","year":"1985","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.leukres.2011.02.021_bib0050","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"issue":"49","key":"10.1016\/j.leukres.2011.02.021_bib0055","first-page":"502","article-title":"Comprehensive Geriatric Assessment adds information to Eastern Cooperative Oncology Group Performance Status in elderly cancer patients: an Italian Group for Geriatric Oncology Study","volume":"20","author":"Repetto","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2011.02.021_bib0060","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2190\/UURL-2RYU-WRYD-EY3K","article-title":"A measure of primary sociobiological functions","volume":"6","author":"Katz","year":"1976","journal-title":"Int J Health Serv"},{"key":"10.1016\/j.leukres.2011.02.021_bib0065","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/geront\/9.3_Part_1.179","article-title":"Assessment of older people: self-maintaining and instrumental activities of daily living","volume":"9","author":"Lawton","year":"1969","journal-title":"Gerontologist"},{"key":"10.1016\/j.leukres.2011.02.021_bib0070","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1532-5415.1968.tb02103.x","article-title":"Cumulative illness rating scale","volume":"16","author":"Linn","year":"1968","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.leukres.2011.02.021_bib0075","doi-asserted-by":"crossref","unstructured":"Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, Pinto A, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Gore SD, Schiffer CA, Kantarjian H. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006;108:419\u2013425.","DOI":"10.1182\/blood-2005-10-4149"},{"key":"10.1016\/j.leukres.2011.02.021_bib0080","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/cncr.22496","article-title":"A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment","volume":"109","author":"Burnett","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2011.02.021_bib0085","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1182\/asheducation-2007.1.420","article-title":"Prognostic Factors in Elderly Patients with AML and the Implications for Treatment","author":"Erba","year":"2007","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.leukres.2011.02.021_bib0090","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/cncr.22891","article-title":"Valproic acid for the treatment of myeloid malignancies","volume":"110","author":"Kuendgen","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2011.02.021_bib0095","doi-asserted-by":"crossref","first-page":"542","DOI":"10.3324\/haematol.10758","article-title":"Effect of histone deacetylase inhibitor valproic acid on progenitor cells of acute myeloid leukemia","volume":"92","author":"Bug","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2011.02.021_bib0100","doi-asserted-by":"crossref","first-page":"8903","DOI":"10.1158\/0008-5472.CAN-05-2726","article-title":"Sequential valproic acid\/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia","volume":"66","author":"Cimino","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2011.02.021_bib0105","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/cncr.21132","article-title":"Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid","volume":"104","author":"Pilatrino","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2011.02.021_bib0110","first-page":"986","article-title":"Valproic acid and all-trans retinoic acid for the treatment of elderly patients with acute myeloid leukemia","volume":"90","author":"Raffoux","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2011.02.021_bib0115","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/j.1365-2141.2008.07449.x","article-title":"Elevated FOSB-expression; a potential marker of valproate sensitivity in AML","volume":"144","author":"Khanim","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2011.02.021_bib0120","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1182\/blood-2006-03-009142","article-title":"Phase 1\/2 study of the combination of 5-aza-2\u2032-deoxycytidine with valproic acid in patients with leukemia","volume":"108","author":"Garcia-Manero","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.02.021_bib0125","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1182\/blood-2007-03-078576","article-title":"Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome","volume":"110","author":"Soriano","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.02.021_bib0130","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJM198312293092602","article-title":"Response of preleukemic syndromes to continuous infusion of low-dose cytarabine","volume":"309","author":"Wisch","year":"1983","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2011.02.021_bib0135","first-page":"196","article-title":"Treatment of leukemia with low-dose Ara-C: a study of 160 cases","volume":"12","author":"Degos","year":"1985","journal-title":"Semin Oncol"},{"key":"10.1016\/j.leukres.2011.02.021_bib0140","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1365-2141.1984.tb02899.x","article-title":"Low dose cytosine arabinoside: partial remission of acute myeloid leukaemia without evidence of differentiation induction","volume":"57","author":"Leyden","year":"1984","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2011.02.021_bib0145","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1365-2141.1979.tb01157.x","article-title":"Differentiation of myeloid leukaemic cells: new possibilities for therapy","volume":"42","author":"Baccarani","year":"1979","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2011.02.021_bib0150","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1158\/1078-0432.CCR-06-2762","article-title":"Effect of cytarabine and decitabine in combination in human leukemic cell lines","volume":"13","author":"Qin","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2011.02.021_bib0155","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1182\/blood-2005-09-008086","article-title":"Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor","volume":"108","author":"Sanchez-Gonzalez","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.02.021_bib0160","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.leukres.2005.04.018","article-title":"Increase in Ara-C cytotoxicity in the presence of valproate, a histone deacetylase inhibitor, is associated with the concurrent expression of cyclin D1 and p27(Kip 1) in acute myeloblastic leukemia cells","volume":"29","author":"Siitonen","year":"2005","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2011.02.021_bib0165","doi-asserted-by":"crossref","unstructured":"D\u00f6hner H, Estey EH, Amadori S, Appelbaum FR, B\u00fcchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz MA, Sierra J, Tallman, MS, L\u00f6wenberg B, Bloomfield CD. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010;115:453\u201374.","DOI":"10.1182\/blood-2009-07-235358"},{"key":"10.1016\/j.leukres.2011.02.021_bib0170","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/cncr.21723","article-title":"Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2011.02.021_bib0175","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/hon.889","article-title":"Comorbidities and FLT3-ITD abnormalities as independent prognostic indicators of survival in Elderly acute myeloid leukaemia patients","volume":"27","author":"Breccia","year":"2009","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.leukres.2011.02.021_bib0180","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0959-8049(99)00319-6","article-title":"Measuring comorbidity in older cancer patients","volume":"36","author":"Extermann","year":"2000","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.leukres.2011.02.021_bib0185","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1200\/JCO.2007.10.6559","article-title":"Comprehensive geriatric assessment for older patients with cancer","volume":"25","author":"Extermann","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2011.02.021_bib0190","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1002\/cncr.23855","article-title":"Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia","volume":"113","author":"Roboz","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2011.02.021_bib0195","doi-asserted-by":"crossref","first-page":"5002","DOI":"10.1158\/1078-0432.CCR-09-0494","article-title":"Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes","volume":"15","author":"Voso","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2011.02.021_bib0200","doi-asserted-by":"crossref","unstructured":"Kim, D.-Y., Lee, J.-H., Lee, J.-H., Lee, K.-H., Kim, Y.-K., Ahn, J.S., Kim, H.-J., Kim, I., Yoon, S.-S., Park, S., Bae, S.H., Bang, S.-M., Lee, H.G., Shin, H.-J., Lee, J.H., Min, Y.H., Won, J.-H., Mun, Y.-C., Oh, D., & Korean Society of Hematology AML\/MDS Working Party. Comparison of various criteria in predicting treatment response and prognosis of patients with myelodysplastic syndrome treated with azacitidine. Ann Hematol 2009.","DOI":"10.1007\/s00277-009-0771-1"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212611001123?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212611001123?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T09:05:41Z","timestamp":1592471141000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212611001123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["S0145212611001123"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2011.02.021","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8]]}}}